Oncology Nutrition Market

Executive Summary

Oncology Nutrition Market was valued at US $2.03 billion in 2021 and is projected to grow at 9.02% CAGR over the forecast period to reach US $3.40 billion by 2027. Oncology Nutrition Market represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $1.38 billion opportunity in 2027 over 2021.

Oncology Nutrition from Consainsights analyses the Oncology Nutrition Market in the Life Sciences industry over the forecast period to 2027.

Oncology Nutrition research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Oncology Nutrition segmentation includes Cancer Type and Geography.

Based on the Cancer Type, the Oncology Nutrition analysis covers Overview – Cancer, Market Size, By Cancer Type, Head and Neck Cancer, Stomach and Gastrointestinal Cancers, Liver Cancer, Pancreatic Cancer, Esophageal Cancer, Lung Cancer, Breast Cancer, Blood Cancer, Other Cancers.

In Cancer Type segment, Overview – Cancer segment has highest cagr growth of 7.98%.

Based on the region, the Oncology Nutrition analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Abbott Laboratories, Nestlé, Danone, Fresenius Kabi, B. Braun and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Cancer Type

Introduction

In 2021, Overview – Cancer segment has the highest revenue of US $0.78 billion and is expected to grow at CAGR of 7.98% by 2027 Overview – Cancer segment has highest cagr growth of 7.98%.

Overview – Cancer

Overview – Cancer segment was valued at US $0.66 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $1.31 billion by 2027. Overview – Cancer segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.53 billion opportunity in 2027 over 2021.

Market Size, By Cancer Type

Market Size, By Cancer Type segment was valued at US $0.41 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $0.81 billion by 2027. Market Size, By Cancer Type segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.33 billion opportunity in 2027 over 2021.

Head and Neck Cancer

Head and Neck Cancer segment was valued at US $0.25 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $0.50 billion by 2027. Head and Neck Cancer segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.20 billion opportunity in 2027 over 2021.

Stomach and Gastrointestinal Cancers

Stomach and Gastrointestinal Cancers segment was valued at US $0.16 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $0.31 billion by 2027. Stomach and Gastrointestinal Cancers segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.13 billion opportunity in 2027 over 2021.

Liver Cancer

Liver Cancer segment was valued at US $0.09 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $0.18 billion by 2027. Liver Cancer segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.

Pancreatic Cancer

Pancreatic Cancer segment was valued at US $0.06 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $0.12 billion by 2027. Pancreatic Cancer segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.05 billion opportunity in 2027 over 2021.

Esophageal Cancer

Esophageal Cancer segment was valued at US $0.04 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $0.07 billion by 2027. Esophageal Cancer segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.

Lung Cancer

Lung Cancer segment was valued at US $0.02 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $0.04 billion by 2027. Lung Cancer segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.02 billion opportunity in 2027 over 2021.

Breast Cancer

Breast Cancer segment was valued at US $0.01 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $0.02 billion by 2027. Breast Cancer segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.

Blood Cancer

Blood Cancer segment was valued at US $0.00 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $0.01 billion by 2027. Blood Cancer segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.00 billion opportunity in 2027 over 2021.

Other Cancers

Other Cancers segment was valued at US $0.01 billion in 2019 and is projected to grow at 7.98% CAGR over the forecast period to reach US $0.01 billion by 2027. Other Cancers segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.00 billion opportunity in 2027 over 2021.